公开(公告)号：BRPI0418262A

公开(公告)日：2007-04-27

申请号：BRPI0418262

申请日：2004-12-16

Applicant: BAXTER INT

Inventor： BROWN RICHARD I ,  MIN KYUNGYOON ,  AKONUR ALP

IPC: B04B5/04 ,  A61M1/36 ,  A61M1/38

Abstract: A separation apparatus and method are employed using a separation channel for rotation about an axis. Such channel includes radially spaced apart inner and outer side wall portions and an end wall portion. An inlet conveys fluid into the channel. A barrier is located in the channel intermediate of the inner and outer side wall portions. A first flow path communicates between upstream and downstream sides of the barrier. A collection region may be located downstream of the barrier for communication with the first flow path. An outer side wall section of the channel may be positioned radially outward of an upstream section thereof. The barrier may join the outer side wall portion along a substantial portion of an axial length of the channel. First and second exit flow paths may allow communication with the channel either upstream or downstream of the barrier or both.

公开(公告)号：ES2717130T3

公开(公告)日：2019-06-19

申请号：ES17173110

申请日：2014-08-08

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： AKONUR ALP ,  LEYPOLDT JOHN KENNETH ,  LO YING-CHENG ,  AGAR BARIS UGAR

公开(公告)号：CA2796505C

公开(公告)日：2018-12-11

申请号：CA2796505

申请日：2011-04-15

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： AKONUR ALP ,  LEYPOLDT JOHN KENNETH ,  LO YING-CHENG ,  AGAR BARIS UGUR

IPC: A61M1/14 ,  A61M1/16

Abstract: A renal failure blood therapy system includes: (i) a renal failure blood therapy machine; (ii) a therapy prescription for a patient treated by the renal failure blood therapy machine to remove a solute from the patient's blood; (iii) a test including multiple blood samples taken at multiple times during a test therapy to determine concentration levels of the solute at each of the multiple times; and (iv) a device programmed to use a kinetic model for the solute in a first instance with at least one of the concentration levels of the solute to estimate at least one estimated patient parameter. The device is further programmed to enable a user to determine at least one of a therapy duration, a therapy frequency, a dialysate flowrate or a blood flowrate for the therapy prescription.

公开(公告)号：AU2015203634A1

公开(公告)日：2015-07-23

申请号：AU2015203634

申请日：2015-06-29

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： AKONUR ALP ,  LEYPOLDT JOHN KENNETH ,  LO YING-CHENG ,  AGAR BARIS UGAR

IPC: G06F19/00 ,  A61M1/14

Abstract: A renal failure blood therapy system includes: (i) a renal failure blood therapy machine; (ii) a therapy prescription for a patient treated by the renal failure blood therapy machine to remove a solute from the patient's blood; (iii) a test including multiple blood samples taken at multiple times during a test therapy to determine concentration levels of the solute at each of the multiple times; and (iv) a device programmed to use a kinetic model for the solute in a first instance with at least one of the concentration levels of the solute to estimate at least one estimated patient parameter. The device is further programmed to enable a user to determine at least one of a therapy duration, a therapy frequency, a dialysate flowrate or a blood flowrate for the therapy prescription. 0 C) C) C)C a)A - a CO co C)D Co C -. - 2 ) ca C) CL a) ~0- I O a) d U) (D o 47----ac 0 ) ct = E :, U3 C X= 0 C)U =) I~~~E ED 0 c- L o wC IC) o z2 2 a) , U) 2) ca co ip 0- 1 C C 4 I (D I In _c CI w- c 6 (D C N - - - - - - -

公开(公告)号：AU2011239488B2

公开(公告)日：2015-05-21

申请号：AU2011239488

申请日：2011-04-15

Applicant: BAXTER HEALTHCARE SA ,  BAXTER INT

Inventor： AKONUR ALP ,  LEYPOLDT JOHN KENNETH ,  LO YING-CHENG ,  AGAR BARIS UGAR

IPC: G06F19/00

Abstract: A method of predicting serum phosphorus concentrations in a patient during hemodialysis includes measuring serum phosphorus concentrations of the patient over a hemodialysis treatment session time and an ultrafiltration rate calculated by a difference between pre- and post-dialytic body weight of the patient during an initial hemodialysis treatment session divided by a total treatment time of the treatment session and estimating a phosphorous mobilization clearance and a pre-dialysis distribution volume of phosphorus for the patient. Serum phosphorus concentrations of the patient can then be predicted at any time during any hemodialysis treatment session with the estimated phosphorous mobilization clearance and pre-dialysis distribution volume of phosphorus of the patient.

公开(公告)号：MX2012000388A

公开(公告)日：2012-03-07

申请号：MX2012000388

申请日：2010-06-02

Applicant: BAXTER INT

Inventor： AKONUR ALP ,  LO YING-CHENG ,  PRICHARD SARAH STOBO

IPC: A61M1/28

Abstract: Se describe una prueba de equilibrio peritoneal simplificada (S-PET). En lugar de una prueba de equilibrio peritoneal prolongada (PET), el procedimiento simplificado no requiere muestra de sangre y puede usar datos a partir de tan pocas como dos o tres muestras para clasificar una membrana peritoneal de un usuario. Normalmente, una membrana peritoneal o peritoneo de un paciente de diálisis, u otra persona, es clasificada como una membrana de alto transporte, membrana de transporte de promedio alto, una membrana de transporte de promedio bajo o una membrana de transporte bajo. La S-PET puede ser realizada en casa por un usuario sin la necesidad de presentar una muestra de sangre. Kits para analizar las muestras pueden ser suministrados para uso en el hogar. Los kits pueden usar tiras desechables, analizadores de microfluidos o reactivos químicos, o pueden incluir alternativamente equipo de análisis reutilizable, tal como equipo de análisis óptico o de conductividad.

公开(公告)号：CA2796496A1

公开(公告)日：2011-10-20

申请号：CA2796496

申请日：2011-04-15

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： AKONUR ALP ,  LEYPOLDT JOHN KENNETH ,  LO YING-CHENG ,  AGAR BARIS UGUR

IPC: G06F19/00

Abstract: A method of predicting serum phosphorus concentrations in a patient during hemodialysis includes measuring serum phosphorus concentrations of the patient over a hemodialysis treatment session time and an ultrafiltration rate calculated by a difference between pre- and post-dialytic body weight of the patient during an initial hemodialysis treatment session divided by a total treatment time of the treatment session and estimating a phosphorous mobilization clearance and a pre-dialysis distribution volume of phosphorus for the patient. Serum phosphorus concentrations of the patient can then be predicted at any time during any hemodialysis treatment session with the estimated phosphorous mobilization clearance and pre-dialysis distribution volume of phosphorus of the patient.

公开(公告)号：AU2003300951A1

公开(公告)日：2004-07-22

申请号：AU2003300951

申请日：2003-12-16

Applicant: BAXTER INT

Inventor： DAVIS SHAWN ,  ZHIZHIN NIKOLAY ,  KILLE ERIC J ,  WESTBERG TOM ,  LABONTE JUDITH ,  JOHNSTON JOHN F ,  OTTINO JULIO ,  LEIBSON ABRAHAM ,  PENNINGTON DAVID W ,  PAWLAK KENNETH E ,  MORIARITY JULIE A ,  SLEPICKA JANE S ,  JOHNSON KENNETH M ,  DAHAN MEIR ,  SHADMAN SOHAIL ,  JONES MARK B ,  WEST RICHARD L ,  LO YING-CHENG ,  MUI TAT CHI ,  AKONUR ALP ,  YARDIMCI ATIF

IPC: A61B20060101

Abstract: Treatment apparatus, system and method are disclosed for treating a biological fluid, such as blood or blood components. The treatment may include but isnot limited to inactivation of pathogens in red cell concentrate. The system may include a disposable fluid circuit assembly and a reusable controller that controls flow through the fluid circuit for reconstituting, if necessary, a treating agent, combining the treating agent with a biological fluid and mixing the agent and biological fluid. An optional quenching agent may also be used.

公开(公告)号：CA2796496C

公开(公告)日：2018-03-20

申请号：CA2796496

申请日：2011-04-15

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： AKONUR ALP ,  LEYPOLDT JOHN KENNETH ,  LO YING-CHENG ,  AGAR BARIS UGUR

IPC: A61B5/155 ,  A61B5/145 ,  A61M1/16 ,  A61M1/34

Abstract: A method of predicting serum phosphorus concentrations in a patient during hemodialysis includes measuring serum phosphorus concentrations of the patient over a hemodialysis treatment session time and an ultrafiltration rate calculated by a difference between pre- and post-dialytic body weight of the patient during an initial hemodialysis treatment session divided by a total treatment time of the treatment session and estimating a phosphorous mobilization clearance and a pre-dialysis distribution volume of phosphorus for the patient. Serum phosphorus concentrations of the patient can then be predicted at any time during any hemodialysis treatment session with the estimated phosphorous mobilization clearance and pre-dialysis distribution volume of phosphorus of the patient.

公开(公告)号：AU2015203634C1

公开(公告)日：2018-01-25

申请号：AU2015203634

申请日：2015-06-29

Applicant: BAXTER HEALTHCARE SA ,  BAXTER INT

Inventor： AKONUR ALP ,  LEYPOLDT JOHN KENNETH ,  LO YING-CHENG ,  AGAR BARIS UGAR

IPC: G06F19/00 ,  A61M1/14

Abstract: A renal failure blood therapy system includes: (i) a renal failure blood therapy machine; (ii) a therapy prescription for a patient treated by the renal failure blood therapy machine to remove a solute from the patient's blood; (iii) a test including multiple blood samples taken at multiple times during a test therapy to determine concentration levels of the solute at each of the multiple times; and (iv) a device programmed to use a kinetic model for the solute in a first instance with at least one of the concentration levels of the solute to estimate at least one estimated patient parameter. The device is further programmed to enable a user to determine at least one of a therapy duration, a therapy frequency, a dialysate flowrate or a blood flowrate for the therapy prescription. 0 C) C) C)C a)A - a CO co C)D Co C -. - 2 ) ca C) CL a) ~0- I O a) d U) (D o 47----ac 0 ) ct = E :, U3 C X= 0 C)U =) I~~~E ED 0 c- L o wC IC) o z2 2 a) , U) 2) ca co ip 0- 1 C C 4 I (D I In _c CI w- c 6 (D C N - - - - - - -